FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die from their disease and current chemotherapy treatment only marginally increases survival. Novel therapies targeting receptor tyrosine kinases or activated oncogenes may improve outcome. Hence, it is necessary to stratify patie...

Full description

Bibliographic Details
Main Authors:	Lucie C Kompier, Irene Lurkin, Madelon N M van der Aa, Bas W G van Rhijn, Theo H van der Kwast, Ellen C Zwarthoff
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2010-11-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC2972209?pdf=render

Internet

http://europepmc.org/articles/PMC2972209?pdf=render

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

Internet

Similar Items